Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, et al. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. Plos One. 2014; 9(1): e86301.
DOI: 10.1371/journal.pone.0086301
Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Review Annu Rev Physiol. 2013; 75: 503-33.
DOI: 10.1146/annurev-physiol-030212-183727
Martín Vírgala J, Fernández-Villabrille S, Martín-Carro B, Tamargo-Gómez I, Navarro-González JF, Mora-Fernández C, et al. Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment. Nutrients. 2023; 15(6): 1470.
DOI: 10.3390/nu15061470
Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, et al. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci U S A. 2019; 116(23): 11418-27.
DOI: 10.1073/pnas.1815166116
Bon N, Frangi G, Sourice S, Guicheux J, Beck-Cormier S, Beck L. Phosphate-dependent FGF23 secretion is modulated by PiT2/Slc20a2. Mol Metab. 2018; 11: 197-204.
DOI: 10.1016/j.molmet.2018.02.007
Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy J Clin Invest. 2011; 121: 4393–408.
DOI: 10.1172/JCI46122
Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C et al. Activation of cardiac fibroblast growth factor Receptor 4 causes left ventricular hypertrophy. Cell Metabolism. 2015; 22: 1020–32.
DOI: 10.1016/j.cmet.2015.09.002
Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. Plos One. 2013; 8: e60658.
DOI: 10.1371/journal.pone.0060658
Chen K, Wang S, Sun QW, Zhang B, Ullah M, Sun Z. Klotho deficiency causes heart aging via impairing the Nrf2-GR pathway. Circ Res. 2021; 128(4): 492–507.
DOI: 10.1161/CIRCRESAHA.120.317348
Xie J, Yoon J, An SW, Kuro-o M, Huang CL. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol. 2015; 26(5): 1150–60.
DOI: 10.1681/ASN.2014040325
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51.
DOI: 10.1038/36285
Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22(1): 124–36.
DOI: 10.1681/ASN.2009121311
Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007; 71(12): 1262-70.
DOI: 10.1038/sj.ki.5002241
Carrillo-López N, Panizo S, Alonso-Montes C, Martínez-Arias L, Avello N, Sosa P, Dusso AS, et al. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. Nephrol Dial Transplant. 2019; 34(6): 934-41.
DOI: 10.1093/ndt/gfy287
Martínez-Arias L, Panizo-García S, Martín-Vírgala J, Martín-Carro B, Fernández-Villabrille S, Avello-Llano N, et al. Contribución de fósforo y PTH al desarrollo de hipertrofia y fibrosis cardiaca en un modelo experimental de insuficiencia renal crónica. Nefrología. 2021; 1(6): 640–51.
DOI: 10.1016/j.nefro.2021.02.001
Naves-Díaz M, Cabezas-Rodríguez I, Barrio-Vázquez S, Fernández E, Díaz-López JB, Cannata-Andía JB. Low calcidiol levels and risk of progression of aortic calcification. Osteoporos Int. 2012; 23(3): 1177-82.
DOI: 10.1007/s00198-011-1550-0
Schmidt N, Brandsch C, Kühne H, Thiele A, Hirche F, Stangl GI. Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS One. 2012; 7(4): e35316.
DOI: 10.1371/journal.pone.0035316
Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293(18): 2257-64.
DOI: 10.1001/jama.293.18.2257
Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011; 26: 1938–47.
Berdud I, Martin-Malo A, Almaden Y, Aljama P, Rodriguez M, Felsenfeld AJ. The PTH-calcium relationnship during a range of infused PTH doses in the parathyroidectomized rat. Calcif Tissue Int, 1998; 62(5): 457-61.
DOI: 10.1007/s002239900460
Fernández Villabrille S, Martín Carro B, Martín Vírgala J, Alonso Montes C, Palomo Antequera C, García Castro R, et al. MicroRNA-145 and microRNA-486 are potential serum biomarkers for vascular smooth muscle cells osteogenic differentiation. Nephrol Dial Transplant. 2023; 38(7): 1729-40.
DOI: 10.1093/ndt/gfad027
Fernández-Villabrille S, Martín-Carro B, Martín-Vírgala J, Alonso-Montes C, Fernández-Fernández A, Martínez-Salgado C, et al. Phosphorus May Induce Phenotypic Transdifferentiation of Vascular Smooth Muscle Cells through the Reduction of microRNA-145. Nutrients. 2023; 15(13): 2918.
DOI: 10.3390/nu15132918
Carrillo-López N, Panizo S, Arcidiacono MV, de la Fuente S, Martínez-Arias L, Ottaviano E, et al. Vitamin D treatment prevents uremia-induced reductions in aortic microRNA-145 attenuating osteogenic differentiation despite hyperphosphatemia. Nutrients. 2022; 14(13): 2589.
DOI: 10.3390/nu14132589
Caus M, Alonso-Montes C, Fernandez-Martin JL, Marti-Antonio M, Bozic M, Valdivielso JM. Vitamin D receptor from VSMCs regulates vascular calcification during CKD: A potential role for miR-145a. Arterioscler Thromb Vasc Biol. 2023; 43(8): 1533-48.
DOI: 10.1161/ATVBAHA.122.318834
Rroji M, Figurek A, Spasovski G. Should we consider the cardiovascular system while evaluating CKD-MBD? Toxins. 2020; 12: 36.
DOI: 10.3390/toxins12030140
Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth muscle cells in vascular calcification: Implications in atherosclerosis and arterial stiffness. Vol. 114, Cardiovascular Research. Oxford University Press; 2018. p. 590–600.
DOI: 10.1093/cvr/cvy010
Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease a systematic review and meta-analysis. Vol. 305, JAMA. 2011; 305(11): 1119-27.
DOI: 10.1001/jama.2011.308
Fernández-Martín JL, Dusso A, Martínez Camblor P, Dionisi MP, Floege J, Ketteler M, et al. Serum phosphate, optimal timing, and range associated with patient survival in haemodialysis: the COSMOS study. Nephrol Dial Transplant. 2019; 34: 673-81.
DOI: 10.1093/ndt/gfy093
Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study. Nephrol Dial Transplant. 2015; 30(9): 1542–51.
DOI: 10.1093/ndt/gfv099
Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D. The role of phosphate in kidney disease. Nat Rev Nephrol. 2017; 13(1): 27-38.
DOI: 10.1038/nrneph.2016.164
Chang WX, Xu N, Kumagai T, Shiraishi T, Kikuyama T, Omizo H, et al. The impact of normal range of serum phosphorus on the incidence of end-stage renal disease by a propensity score analysis. PLoS One. 2016; 11(4): e0154469.
DOI: 10.1371/journal.pone.0154469
Barrera-Baena P, Rodríguez-García M, Rodríguez-Rubio E, González-Llorente L, Ortiz A, Zoccali C, et al. Serum phosphate is associated with increased risk of bone fragility fractures in hemodialysis patients. Nephrol Dial Transplant. 2023; 39(4): 618-26.
DOI: 10.1093/ndt/gfad190
Torregrosa JV, Bover J, Rodríguez Portillo M, González Parra E, Arenas MD, Caravaca F, et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica: 2021 (SEN-MM). Nefrología. 2022; 42: 1-37.
DOI: 10.1016/j.nefro.2022.03.007
Español
English
Número de descargas:
100
Número de visitas:
552
Citas:
0
